Akston Biosciences Corporation specializes in bringing protein therapeutics through the major phases of development, faster, more cost-effectively, and with a higher likelihood of success. We invent novel therapeutics using our Ambifect® Fc-fusion platform. We develop and manufacture our therapeutics in our Animal Health protein manufacturing facility.
Akston designed and built a multi-kilogram-scale GMP biologics factory dedicated to Animal Health, with full Process Development and Quality Control capabilities, all under a state-of-the-art Quality Management System.
Each of our products is derived from the Ambifect® Fc-fusion protein platform, leveraging common manufacturing and analytical processes to speed development and reduce regulatory risk.
Akston licenses its candidates to go-to-market partners and also maintains close involvement with those partners in the product development process.
2023 recipient at Animal Health Summit
Subsidiary of Akston for human vaccine candidates
Subsidiary of Akston for human diabetes candidates
AKS-452 in Netherlands
AKS-452 in India
AKS-452 in India
AKS-452 in Netherlands
AKS-452 in Netherlands
Feline once-a-week diabetes treatment
AKS-452 in Netherlands
Once-a-week diabetes treatment for dogs
Once-a-week diabetes treatment for cats
Canine once-a-week diabetes treatment
Supporting Type 1 Diabetes Research
AKS-321d and AKS-425c
For Type 1 Diabetes Research
Type 1 Diabetes Intervention
Beverly, Massachusetts
Akston founded by the team from SmartCells, Inc.
Sold to Merck & Co. in one of the largest preclinical pharmaceutical acquisitions in history